Largest benefits seen for patients older than 60 years with no increased risk for hemorrhagic complications
COVID-19 Vaccination Not Linked to Peripartum Adverse Outcomes
Large population-based cohort of more than 22,000 women shows no increased risks with vaccination during pregnancy
Risk, Burden of Diabetes Up After Acute SARS-CoV-2 Infection
Risks and burdens of postacute outcomes increased in graded manner based on COVID-19 severity
CDC Supports Second COVID-19 Booster for Americans 50 Years and Older
Echoing the FDA, the CDC also supported a second booster for ‘certain immune-compromised individuals’
Immune Response to SARS-CoV-2 Infection Persists in Children
Ninety-six percent of those with evidence of nucleocapsid antibodies at baseline still had antibodies more than six months later
No Adverse Outcomes Seen With SARS-CoV-2 Vaccination in Pregnancy
No significantly increased risk reported for preterm birth, stillbirth, SGA, low Apgar score, or neonatal care admission
2019 to 2020 Saw Risk-Linked Deaths From Heart Disease, Stroke Up
Highest risk-associated increases were seen in non-Hispanic Black people followed by Hispanics, non-Hispanic Asian or Pacific Islanders
FDA Approves Second COVID-19 Booster for Americans 50+
Agency also authorized a second booster for Americans 12 and older who are immune-compromised
Memory Deficits Seen in Individuals With ‘Long COVID’
Deficits increased with severity of ongoing self-reported symptoms; severity of initial illness did not influence later cognitive performance
$24 Million in Grants Will Help End the HIV Epidemic
Gilead Sciences, Inc. today announced $24 million in new grants that will help reduce health disparities, improve access to quality healthcare, advance medical education and support local communities most impacted by the HIV epidemic and COVID-19 pandemic.
Gilead confirmed the Zeroing In: Ending the HIV Epidemic program will support 116 organizations in 41 countries.
The funding recipients will focus on advancing at least one of three focus areas: Comprehensive HIV Innovation, Digital Health Innovation, and Community Outreach and Education.